semaglutide and cardiovascular Outcomes in Patients with Type 2 Diabetes Semaglutide reduces cardiovascular events in

Many people feel more comfortable managing their progress privately

GLP-1 tablets may lead to more variable absorption patterns, particularly in the early weeks of therapy

It works by simultaneously activating three incretin-related receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor

The ongoing CONFIDENCE trial (NCT05254002) is an international randomised controlled double-blind trial that will directly assess the effects of finerenone plus empagliflozin on albuminuria and characterise the efficacy and safety of this drug combination in the setting of type 2 diabetes

Studies show that rapid weight loss and restricted caloric intake increase the risk of deficiencies in vitamin B12, iron, calcium, and vitamin D

Spinach, mushrooms, peppers, zucchini, and tomatoes add volume and nutrients to egg dishes